17-61801469-T-C
Variant summary
Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6_Very_StrongBP7
The NM_032043.3(BRIP1):c.924A>G(p.Lys308Lys) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000149 in 1,606,726 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Consequence
NM_032043.3 synonymous
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -13 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152202Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000399 AC: 10AN: 250614Hom.: 0 AF XY: 0.0000369 AC XY: 5AN XY: 135560
GnomAD4 exome AF: 0.0000144 AC: 21AN: 1454524Hom.: 0 Cov.: 31 AF XY: 0.0000138 AC XY: 10AN XY: 723974
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152202Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74368
ClinVar
Submissions by phenotype
not provided Uncertain:1Benign:4
- -
The BRIP1 p.Lys308Lys variant was not identified in the literature nor was it identified in Cosmic, MutDB and Zhejiang Colon Cancer Database. The variant was identified in dbSNP (ID: rs374974885) “With Likely benign” allele, ClinVar (classified as likely benign by Invitae and GeneDx) and Clinvitae database (2X as likely benign). The variant was identified in control databases in 12 of 276616 chromosomes at a frequency of 0.00004 increasing the likelihood that this may be a low frequency benign variant in certain populations of origin (Genome Aggregation Consortium Feb 27, 2017). The p.Lys308Lys variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site; however, the c.924A>G occurs 6 nucleotides into exon 08, and 1 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. -
- -
- -
- -
Hereditary cancer-predisposing syndrome Benign:2
- -
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
not specified Benign:1
- -
Breast and/or ovarian cancer Benign:1
- -
Familial cancer of breast;C1836860:Fanconi anemia complementation group J Benign:1
- -
Familial cancer of breast Benign:1
This variant is considered benign. This variant is a silent/synonymous amino acid change and it is not expected to impact splicing. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at